Your browser doesn't support javascript.
loading
Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox, Naomi; Dumont, Martine; González-Neira, Anna; Carvalho, Sara; Joly Beauparlant, Charles; Crotti, Marco; Luccarini, Craig; Soucy, Penny; Dubois, Stéphane; Nuñez-Torres, Rocio; Pita, Guillermo; Gardner, Eugene J; Dennis, Joe; Alonso, M Rosario; Álvarez, Nuria; Baynes, Caroline; Collin-Deschesnes, Annie Claude; Desjardins, Sylvie; Becher, Heiko; Behrens, Sabine; Bolla, Manjeet K; Castelao, Jose E; Chang-Claude, Jenny; Cornelissen, Sten; Dörk, Thilo; Engel, Christoph; Gago-Dominguez, Manuela; Guénel, Pascal; Hadjisavvas, Andreas; Hahnen, Eric; Hartman, Mikael; Herráez, Belén; Jung, Audrey; Keeman, Renske; Kiechle, Marion; Li, Jingmei; Loizidou, Maria A; Lush, Michael; Michailidou, Kyriaki; Panayiotidis, Mihalis I; Sim, Xueling; Teo, Soo Hwang; Tyrer, Jonathan P; van der Kolk, Lizet E; Wahlström, Cecilia; Wang, Qin; Perry, John R B; Benitez, Javier; Schmidt, Marjanka K; Schmutzler, Rita K.
Afiliação
  • Wilcox N; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Dumont M; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • González-Neira A; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Carvalho S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Joly Beauparlant C; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Crotti M; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Luccarini C; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Soucy P; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Dubois S; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Nuñez-Torres R; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Pita G; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Gardner EJ; MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Alonso MR; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Álvarez N; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Baynes C; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Collin-Deschesnes AC; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Desjardins S; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
  • Becher H; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Behrens S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Castelao JE; Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
  • Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cornelissen S; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dörk T; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Engel C; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Gago-Dominguez M; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
  • Guénel P; LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.
  • Hadjisavvas A; Cancer Genetics and Epidemiology Group, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Foundation, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  • Hahnen E; Team 'Exposome and Heredity,' CESP, Gustave Roussy, INSERM, University Paris-Saclay, UVSQ, Villejuif, France.
  • Hartman M; Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Herráez B; Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Jung A; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore City, Singapore.
  • Keeman R; Department of Surgery, National University Health System, Singapore City, Singapore.
  • Kiechle M; Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
  • Li J; Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Lush M; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Michailidou K; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Panayiotidis MI; Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
  • Sim X; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore City, Singapore. lijm1@gis.a-star.edu.sg.
  • Teo SH; Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Tyrer JP; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • van der Kolk LE; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Wahlström C; Biostatistics Unit, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Wang Q; Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Perry JRB; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore City, Singapore.
  • Benitez J; Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Malaysia.
  • Schmidt MK; Department of Surgery, Faculty of Medicine, University of Malaya, UM Cancer Research Institute, Kuala Lumpur, Malaysia.
  • Schmutzler RK; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Nat Genet ; 55(9): 1435-1439, 2023 09.
Article em En | MEDLINE | ID: mdl-37592023
Linkage and candidate gene studies have identified several breast cancer susceptibility genes, but the overall contribution of coding variation to breast cancer is unclear. To evaluate the role of rare coding variants more comprehensively, we performed a meta-analysis across three large whole-exome sequencing datasets, containing 26,368 female cases and 217,673 female controls. Burden tests were performed for protein-truncating and rare missense variants in 15,616 and 18,601 genes, respectively. Associations between protein-truncating variants and breast cancer were identified for the following six genes at exome-wide significance (P < 2.5 × 10-6): the five known susceptibility genes ATM, BRCA1, BRCA2, CHEK2 and PALB2, together with MAP3K1. Associations were also observed for LZTR1, ATR and BARD1 with P < 1 × 10-4. Associations between predicted deleterious rare missense or protein-truncating variants and breast cancer were additionally identified for CDKN2A at exome-wide significance. The overall contribution of coding variants in genes beyond the previously known genes is estimated to be small.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exoma / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Nat Genet Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exoma / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Nat Genet Ano de publicação: 2023 Tipo de documento: Article